KR20060113699A - 치환된 이소퀴놀리논 - Google Patents

치환된 이소퀴놀리논 Download PDF

Info

Publication number
KR20060113699A
KR20060113699A KR1020067008642A KR20067008642A KR20060113699A KR 20060113699 A KR20060113699 A KR 20060113699A KR 1020067008642 A KR1020067008642 A KR 1020067008642A KR 20067008642 A KR20067008642 A KR 20067008642A KR 20060113699 A KR20060113699 A KR 20060113699A
Authority
KR
South Korea
Prior art keywords
alkyl
cycloalkyl
hydrogen
group
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020067008642A
Other languages
English (en)
Korean (ko)
Inventor
로버트 엠. 스카보로우
킴 에이. 켄-마귀레
챨스 케이. 말로우
마크 에스. 스미쓰
자오밍 쟁
Original Assignee
포톨라 파마슈티컬스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 포톨라 파마슈티컬스, 인코포레이티드 filed Critical 포톨라 파마슈티컬스, 인코포레이티드
Publication of KR20060113699A publication Critical patent/KR20060113699A/ko
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020067008642A 2003-10-03 2004-09-29 치환된 이소퀴놀리논 Ceased KR20060113699A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50840203P 2003-10-03 2003-10-03
US60/508,402 2003-10-03

Publications (1)

Publication Number Publication Date
KR20060113699A true KR20060113699A (ko) 2006-11-02

Family

ID=34434908

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067008642A Ceased KR20060113699A (ko) 2003-10-03 2004-09-29 치환된 이소퀴놀리논

Country Status (10)

Country Link
US (1) US7294635B2 (cg-RX-API-DMAC7.html)
EP (1) EP1667989A4 (cg-RX-API-DMAC7.html)
JP (1) JP4879745B2 (cg-RX-API-DMAC7.html)
KR (1) KR20060113699A (cg-RX-API-DMAC7.html)
CN (1) CN1863789B (cg-RX-API-DMAC7.html)
AU (1) AU2004279809B2 (cg-RX-API-DMAC7.html)
CA (1) CA2539882A1 (cg-RX-API-DMAC7.html)
IL (1) IL174445A (cg-RX-API-DMAC7.html)
MX (1) MXPA06003625A (cg-RX-API-DMAC7.html)
WO (1) WO2005035520A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007003836A (es) * 2004-09-29 2007-08-20 Portola Pharm Inc 2h-1,3-benzoxazin-4(3h)-onas sustituidas.
RU2008101924A (ru) * 2005-07-13 2009-08-20 Астразенека Аб (Se) Новые аналоги пиридина
TWI391378B (zh) 2006-03-16 2013-04-01 Astellas Pharma Inc 喹啉酮衍生物或其製藥學上可被容許之鹽
JP2009542641A (ja) * 2006-07-04 2009-12-03 アストラゼネカ アクチボラグ 新規ピリジン類縁体
CA2655629A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab New pyridine analogues
TW200811133A (en) * 2006-07-04 2008-03-01 Astrazeneca Ab New pyridine analogues III 334
US7834023B2 (en) * 2006-09-20 2010-11-16 Portola Pharmaceuticals, Inc. Substituted dihydroquinazolines as platelet ADP receptor inhibitors
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
MX2009007831A (es) 2007-01-22 2010-01-15 Gtx Inc Agentes de union de receptor nuclear.
TW200911755A (en) 2007-04-19 2009-03-16 Astellas Pharma Inc Bicyclic heterocyclic compounds
NZ599556A (en) 2007-05-02 2013-10-25 Portola Pharm Inc Combination therapy with a compound acting as a platelet adp receptor inhibitor
PE20081892A1 (es) * 2007-07-13 2009-02-21 Astrazeneca Ab Nuevos analogos de amino-piridina como agentes antitromboticos
CN103739547B (zh) * 2014-01-03 2015-09-02 沈阳药科大学 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法
ES2718175T3 (es) * 2014-12-02 2019-06-28 Lilly Co Eli Compuestos de 1-oxo-1,2-dihidroisoquinolin-7-il-(tiofen-2-il-5-sustituido)-sulfonamida, formulaciones que contienen esos compuestos, y su uso como inhibidores de AICARFT en el tratamiento de cánceres
CN107428696B (zh) 2015-02-16 2021-08-20 昆士兰大学 磺酰脲和相关化合物及其用途
PT3661925T (pt) 2017-07-07 2022-01-31 Inflazome Ltd Novos compostos de sulfonamida-carboxamida
CN111093773A (zh) 2017-08-15 2020-05-01 英夫拉索姆有限公司 作为nlrp3抑制剂的磺酰脲和磺酰硫脲
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
US12221434B2 (en) 2017-11-09 2025-02-11 Inflazome Limited Sulfonamide carboxamide compounds
PE20210050A1 (es) 2017-11-09 2021-01-08 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida
US11905252B2 (en) 2018-03-02 2024-02-20 Inflazome Limited Compounds
TWI721624B (zh) 2018-10-31 2021-03-11 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
ES2979163T3 (es) 2018-10-31 2024-09-24 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de HPK1
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847925A (en) * 1971-07-15 1974-11-12 En Nom Collectif Science Et Ci Benzenesulfonyl semicarbazides
US5314902A (en) * 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
SE9702774D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
EP1047699A1 (en) 1998-01-15 2000-11-02 Cor Therapeutics, Inc. Platelet adp receptor inhibitors
DE60114994T2 (de) * 2000-02-04 2006-08-03 Portola Pharmaceuticals, Inc., South San Francisco Blutplättchen-adp-rezeptor-inhibitoren
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors

Also Published As

Publication number Publication date
US20050113399A1 (en) 2005-05-26
JP2007507519A (ja) 2007-03-29
JP4879745B2 (ja) 2012-02-22
IL174445A (en) 2012-02-29
EP1667989A4 (en) 2008-08-20
IL174445A0 (en) 2006-08-01
WO2005035520A1 (en) 2005-04-21
CN1863789A (zh) 2006-11-15
CN1863789B (zh) 2010-06-09
MXPA06003625A (es) 2006-08-11
US7294635B2 (en) 2007-11-13
AU2004279809A1 (en) 2005-04-21
EP1667989A1 (en) 2006-06-14
AU2004279809B2 (en) 2010-07-15
CA2539882A1 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
KR20060113699A (ko) 치환된 이소퀴놀리논
EP1668002B1 (en) 2,4-dioxo-3-quinazolinylaryl sulfonylureas
US8680139B2 (en) Anti-neoplastic compounds, compositions and methods
CN101605779B (zh) 作为凝血因子xia抑制剂的芳基丙酰胺、芳基丙烯酰胺、芳基丙炔酰胺或芳基甲基脲类似物
EP2315588B1 (en) 6-1h-imidazo-quinazoline and quinolines derivatives, new mao inhibitors and imidazoline receptor ligands
US7205296B2 (en) Substituted 2H-1,3-benzoxazin-4(3H)-ones
EP0922035B1 (en) Tetrahydroisoquinoline derivatives and their pharmaceutical use
JPWO2006057270A1 (ja) 含窒素3環化合物
JP2005501826A (ja) 置換イソインドールおよびそれらの使用
CA2560098A1 (en) 2-aminoquinazoline derivative
CA2494616A1 (en) Furanthiazole derivatives as heparanase inhibitors
CN117800955A (zh) 2位或4位吡喃酮类衍生物及其药物组合物、制备方法和用途
CN104803914A (zh) 作为Rho激酶抑制剂的六氢氮杂卓氧基苯甲酰胺类化合物
HK1093973B (en) 2,4-dioxo-3-quinazolinylaryl sulfonylureas
HK1111414B (en) Substituted 2h-1,3-benzoxazin-4(3h)-ones

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060503

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090928

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110511

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20120520

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20121105

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20120520

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20110511

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I